ICU Medical (NASDAQ:ICUI) Trading Up 13.7% After Better-Than-Expected Earnings

ICU Medical, Inc. (NASDAQ:ICUI)’s share price rose 13.7% during mid-day trading on Friday following a stronger than expected earnings report. The company traded as high as $192.85 and last traded at $189.0820. Approximately 115,743 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 290,658 shares. The stock had previously closed at $166.37.

The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. ICU Medical’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period last year, the firm posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. ICU Medical reported adjusted EPS of $2.37, well above the $1.91 analyst consensus and up from $2.10 a year earlier. Revenue reached $547.9 million, compared with estimates of $533.4 million, although sales growth was modest at 0.5% year over year. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Full-year guidance is above Wall Street expectations. ICU Medical projected fiscal 2026 EPS of $8.60 to $9.00, compared with the consensus estimate of $7.83. The outlook suggests management expects earnings momentum to continue. ICU Medical Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Analysts raised their valuation expectations. Needham increased its price target from $165 to $187 and assigned a “Buy” rating. Other analysts also lifted targets following the earnings report, reinforcing the favorable market reaction. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Investors should weigh valuation and profitability. Despite the earnings beat, ICU Medical’s reported net margin was just 2.15%, while its elevated valuation leaves less room for execution or guidance disappointments.

Analyst Ratings Changes

Several research analysts recently weighed in on ICUI shares. BTIG Research upped their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler decreased their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Needham & Company LLC lifted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $186.40.

Insider Activity at ICU Medical

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the transaction, the director directly owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ICUI. Maryland State Retirement & Pension System raised its stake in ICU Medical by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after acquiring an additional 70 shares during the last quarter. California Public Employees Retirement System grew its stake in shares of ICU Medical by 0.3% in the 1st quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock valued at $3,934,000 after purchasing an additional 90 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock valued at $803,000 after purchasing an additional 100 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the last quarter. Finally, Lido Advisors LLC lifted its holdings in shares of ICU Medical by 4.5% during the fourth quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock worth $354,000 after purchasing an additional 106 shares during the period. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Trading Up 11.7%

The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The stock has a market capitalization of $4.65 billion, a PE ratio of 100.82, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. The business’s 50-day moving average is $150.66 and its two-hundred day moving average is $140.72.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.